NCT05829057View on ClinicalTrials.gov

The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

June 21, 2025

Conditions
Esophagus CancerBladder CancerLiver CancerOvarian CancerSmall-cell Lung Cancer
Interventions
BIOLOGICAL

Intravenous injection of P-IL-2

Ia :Single dose intravenous injection of P-IL-2；

BIOLOGICAL

P-IL-2 plus Anti-PD-1 Monoclonal Antibody

Ib：P-IL-2 plus Anti-PD-1 Monoclonal Antibody；

Trial Locations (1)

310006

RECRUITING

First affiliated hospital, Zhejiang University, Hangzhou

All Listed Sponsors
collaborator

Zcapsule Pharmaceuticals (Shaoxing) Co., Ltd

INDUSTRY

lead

Zhejiang University

OTHER